NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 1.33 against a street estimate of 0.75 — a beat of 77.3%.
with an average price target of ₹231.45.
CONFIDENT Strong Q1 FY27 start: 17% revenue growth to ₹2,270cr, EBITDA +72% to ₹285cr with 400bp margin expansion. CDMO +19%, CHG +17%, Consumer +mid-teens. Management reaffirms FY27 guidance; targets 25% EBITDA margins by FY30. Q1 FY27 Overseas facilities have favorable margin profiles (75-85% gross margin) but operate below target scale. India gross margins ~55-65%. Operating leverage expected to drive margin expansion as overseas capacity utilizes. Analysts pressed on growth sustainability (management cautious on repeating Q1 %), capex ROI on new facilities (single-digit millions expected), and overseas breakeven timeline (gradual across jurisdictions, faster in North America). Management deflected specific molecule/customer disclosures to public filings. 2026-07-30…
Full summary in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Piramal Pharma Limited — free to start.
Google PlayApp StoreData updated 2026-08-05.